Navigation Links
DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC

supply the vaccine for both civilian and military use."

The Company recently announced the publication of key results with BT-VACC™ showing that mucosal immunization with a multivalent version of the vaccine induces a robust immune response that resulted in protection against several of the natural serotypes of botulinum toxin. BT-VACC™ is composed of a component of what is known as the heavy chain of each of the A, B, and E serotypes of botulinum toxin. The heavy chain component lacks the region of the toxin that is responsible for blocking neurotransmitter functions. The subunits can bind avidly to receptors on the surface of mucosal cells and traverse lung and gastrointestinal tissue to stimulate immunity. Because the binding subunits do not contain the toxic part of the molecule, the vaccine is safe and stimulates antibodies in not only the blood but those antibodies that coat mucosal surfaces. It is thought that antibodies that are present in lung and gastrointestinal secretions will block the uptake of the toxin before entering the bloodstream and reaching peripheral nerves.

About Botulinum Toxin

Botulinum toxin is an extremely potent neurotoxin of bacterial origin that inhibits peripheral nerve function, causing severe and often fatal descending flaccid muscle paralysis. Natural botulism resulting from ingestion of toxin from contaminated food is very rare, but artificially, botulism also can result from bioterrorism and biowarfare. Because extremely small amounts of the toxin can cause neurological effects, it is classified as a category A Biothreat by the CDC. The toxin can enter the body very efficiently through lung tissue and through the gastrointestinal tract, making the threat of purposeful food contamination with botulinum toxin a real possibility as a biological weapon. Because the toxin rapidly enters target neural cells, exposure is difficult to treat with any available therapeutic regimen other than supportive care
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/30/2015)... y LONDRES, August 30, 2015 ... visión holística de l cuidado al ... trayecto   Royal Philips  ... debut europeo de IntelliSpace Cardiovascular , un sistema ... sofisticadas herramientas para acceder, analizar y compartir imágenes cardiovasculares ...
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "12th Annual ... Production" report to their offering. ... Biopharmaceutical Manufacturing Capacity and Production is the most ... organizations, current and projected future capacity and production. ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3CytomX Files Registration Statement for Proposed Initial Public Offering 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... DIEGO, Sept. 19, 2011 Marshall Edwards, Inc. (Nasdaq: ... development of novel therapeutics targeting cancer metabolism, announced today that ... clinical trial of its lead drug candidate ME-143 in patients ... the Sarah Cannon Research Institute, is expected to enroll up ...
... (NYSE: LLY ) will bring one of its ... 2011 Annual Legislative Conference presented by the Congressional Black Caucus ... In attendance will be Eli Lilly and Company,s ... C onnected and E mpowered ...
Cached Medicine Technology:Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 2Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 3Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 4Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference 2
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... Natural Rest ... beneficial effects as sleep aids and calming remedies, which help to improve mood disorders ... of a great deal of research in the field of regenerative medicine conducted by ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products ... Administrative assistant to Executive Assistant to CEO Mitch Gould for Nutritional Products International. ... on your goals. Kathleen graduated from Florida State University with a Bachelor ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... two inventors from Miller Place, N.Y. "I specialize in manual therapy, and my ... addition, it can be used for additional muscle dysfunction throughout the body." , ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder ... mission is to increase acceptance of the chiropractic field in the military. All too ... them. Although Chiropractic was made available to the VA program over a decade ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... discount programs has soared in recent months, according to leading pharmacy ... ... -- AIS,s Drug Benefit News -- Demand for Web-based prescription drug ... according to pharmacy executives who point to the weak economy and ...
... 1,300,000 Adults Living in the U.S. with Congenital Heart ... Senator Richard Durbin (D-IL) and Congressman Zack Space ... time in history, will address the needs of those ... common birth defect that affects approximately one out of ...
... the gift of sound to children in needPISCATAWAY, ... one of the largest manufacturers of hearing instruments ... Quota International to provide free hearing instruments to ... Quota International,s Sound Beginnings Program, Siemens will donate ...
... Calif., March 18 Codexis, Inc. today announced that ... Vice President, Corporate Development from his previous position as ... to Alan Shaw, Ph.D., President and CEO. Dr. ... He joined Codexis in 2005 as Corporate Counsel ...
... Medivation, Inc. (Nasdaq: MDVN ) today ... the U.S. Food and Drug Administration (FDA) to ... its novel androgen receptor antagonist, in patients with ... docetaxel-based chemotherapy. The placebo-controlled, double-blind, multinational trial ...
... usually smaller and more contained, study finds , , WEDNESDAY, March ... can reduce the risk of death by as much as ... at information on 1,044 women who were seen at a ... who had developed a second breast cancer -- 455 with ...
Cached Medicine News:Health News:Online Rx Price Comparison Tools, Drug Discount Card Use Soars in Weak Economy 2Health News:For the First Time in U.S. History, Congress Addresses the Needs of the Congenital Heart Defect Population by Introducing the 'Congenital Heart Futures Act' 2Health News:For the First Time in U.S. History, Congress Addresses the Needs of the Congenital Heart Defect Population by Introducing the 'Congenital Heart Futures Act' 3Health News:Siemens to Donate Hearing Instruments Through Second Annual Partnership With Quota International 2Health News:Siemens to Donate Hearing Instruments Through Second Annual Partnership With Quota International 3Health News:Siemens to Donate Hearing Instruments Through Second Annual Partnership With Quota International 4Health News:Codexis Names Sarret SVP, Corporate Development 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 3Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 4Health News:When Breast Cancer Recurs, Finding Pre-Symptoms Is Key 2
... worlds leading medical technology company and ... for more than a decade, introduces ... The ACT Plus System is a ... determine coagulation endpoints in whole blood, ...
An Innovative New System to Help You Meet the Challenges of Anterior Spine Surgery...
... the Alcon OcuScan RxP Ophthalmic Ultrasound System, ... instrumentation. With improved auto modes and flexible ... to obtain measurements that are both accurate ... by providing high quality eye measurements in ...
... the Atlas+ HF ICD is designed to provide ... and quality of life. The Atlas+ HF ICD ... resynchronization therapy (CRT), and it packs its power ... physiologic-shaped can. In addition to its high energy, ...
Medicine Products: